早期对一种名为CBL-514的实验性注射剂进行的人体试验显示出降低致命性内脏脂肪的潜力。
Early human trials of an experimental injection called CBL-514 have shown potential for reducing deadly visceral fat.
内脏脂肪位于腹部深处，紧紧包裹着内脏器官，它会影响新陈代谢，影响胰岛素抵抗，并可能影响2型糖尿病的发展。美国心脏协会于三月发表的一项研究发现，内脏脂肪与心力衰竭风险的关联程度比体重指数（BMI）更强。
Visceral fat, which sits deep inside the abdomen wrapped around internal organs, affects metabolism, influences insulin resistance and can impact the development of type 2 diabetes. Research published in March by the American Heart Association found that visceral fat had a stronger association with the risk of heart failure than body mass index (BMI).
您的腰围可能揭示BMI未能检测出的隐藏心脏风险，重大研究发现。该试验旨在检测该注射剂是否能减少内脏脂肪沉积，由阿拉巴马大学伯明翰分校的W. Timothy Garvey博士和台湾新北市Caliway生物制药公司的Yu-Fang Ling共同进行。
YOUR WAISTLINE COULD REVEAL A HIDDEN HEART RISK YOUR BMI MISSES, MAJOR STUDY FINDS The trials tested whether the injection could diminish visceral fat deposits, and they were conducted by Dr. W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of Caliway Biopharmaceuticals in New Taipei City, Taiwan.
此前的第二阶段试验已经表明，该药物能够减少皮下脂肪——即位于皮肤直接下方的脂肪层。
Previous phase 2 trials had already shown that the drug could reduce subcutaneous fat, the layer of fat directly beneath the skin.
两项第二阶段试验的MRI扫描显示，接受CBL-514药物治疗的参与者内脏脂肪有所减少，而接受安慰剂治疗的参与者内脏脂肪则有所增加。
MRI scans from two phase 2 trials exhibited a decrease in visceral fat in participants who received the CBL-514 drug, while the visceral fat increased in those who received a placebo drug.
接受CBL-514治疗的参与者每三周注射一次，注射部位位于下腹部，持续时间最长可达12周，剂量最高可达600毫克。注射次数取决于参与者腹部脂肪的厚度。随着脂肪层体积的减少，注射次数也随之减少。
Participants who were given CBL-514 received injections into their lower abdomen every three weeks for up to 12 weeks, with doses of up to 600 milligrams. The number of injections given to participants depended on the thickness of their abdominal fat. As the fat layer decreased in volume, the number of injections also decreased.
CBL-514注射剂能够选择性地引发凋亡——即导致细胞自我毁灭的过程——但仅作用于脂肪细胞，而不对附近的其他细胞造成伤害。
The CBL-514 injection selectively sparks apoptosis—a process which causes cells to self-destruct—but only in fat cells, leaving nearby cells unharmed.
SciTechDaily报道称，在最后一次治疗后四周，接受CBL-514治疗的组别平均脂肪体积降低了12.01%，而接受安慰剂治疗的组别脂肪体积则增加了5.68%。
CLICK HERE FOR MORE LIFESTYLE NEWS Four weeks after the final treatment, the average volume of fat had lowered by 12.01% in the group given CBL-514, while it had increased by 5.68% in the group that received a placebo, SciTechDaily reported.
潜在的美容效果，例如由于皮下脂肪减少导致的腹部变平，对患者具有吸引力，加维承认。
The potential cosmetic effects, such as a flatter stomach due to subcutaneous fat loss, are appealing to patients, Garvey acknowledged.
然而，他指出，更重要的是，注射可导致体重下降、血压和胆固醇改善以及内脏脂肪减少，因为这些因素会影响整体健康。
However, what’s even more important, he noted, is the decrease in body weight, improved blood pressure and cholesterol, and the loss of visceral fat that the injection can cause, as these factors impact overall health.
吸脂术是一种常见的外科美容手术，无法去除内脏脂肪，因此也无法降低由大量内脏脂肪引起的健康风险。
Liposuction, a common surgical cosmetic procedure, cannot remove visceral fat, and thus cannot reduce the health risks caused by a high amount of visceral fat.